REZOLUTE, INC. Form DEFA14A: Additional definitive proxy soliciting materials
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-10-21: Form DEFA14A; Description DEFA14A; Document tm2425798d3_defa14a.htm.
- 2023-04-12: Form DEFA14A; Description DEFA14A; Document tm2312168d2_defa14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2024-10-21 | DEFA14A | DEFA14A | tm2425798d3_defa14a.htm | |
| 2023-04-12 | DEFA14A | DEFA14A | tm2312168d2_defa14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |